NASDAQ:NKTR

Nektar Therapeutics Stock News

Healthcare > Biotechnology

Buy NKTR

*Your capital is at risk

$59.23

+0.670 (+1.14%)

At Close: Jun 03, 2026

Aerie Pharma (AERI) Received its Third Buy in a Row

11:27am, Friday, 27'th Mar 2020

After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this

Analysts' Opinions Are Mixed on These Healthcare Stocks: Xeris Pharmaceuticals (XERS), Spero Therapeutics (SPRO) and aTyr Pharma (LIFE)

11:21am, Friday, 27'th Mar 2020

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS), Spero Therapeutics (SPRO) and aTyr Pharma

Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)

08:12am, Friday, 27'th Mar 2020

Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN) today and set a price target of $72.00. The company's shares closed last

Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)

08:12am, Friday, 27'th Mar 2020

Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price

Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

12:00am, Friday, 27'th Mar 2020

Mizuho Securities Keeps a Buy Rating on uniQure (QURE)

01:15pm, Thursday, 26'th Mar 2020

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure (QURE) today and set a price target of $90.00. The company's shares closed last

Mizuho Securities Keeps a Buy Rating on uniQure (QURE)

01:15pm, Thursday, 26'th Mar 2020

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure (QURE – Research Report) today and set a price

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by